Search results
Delaying Statin Therapy in Diabetes Increases CV Risk
Medscape· 3 days agoPatients with type 1 and 2 diabetes who delay treatment with recommended statin therapy to address...
Opinion | Is Cholesterol Denialism Pseudoscience or Appropriate Medical Care?
MedPage Today· 6 days agoRecently, a cardiologist published a commentary in Medscape arguing that physicians and scientists...
Akira Endo, the Father of Statins, Dies
Medscape· 2 days agoAkira Endo, PhD, the Japanese microbiologist and biochemist known as the father of statins, died at the age of 90 on June 5. Born into a family of...
Should You Take a Fish Oil Supplement? It Really Depends.
Men's Health via Yahoo News· 1 day agoWill those changes reduce your risk of diseases or help you avoid new ones? That’s still being...
Bempedoic Acid Effective in Patients With Obesity
Medscape· 2 days agoBempedoic acid (Nexletol) is safe for people with obesity and is effective at lowering lipid levels and rates of major cardiovascular events, according...
Are Your Prescription Meds Giving You Diabetes?
Mercola· 6 days agoIn the quest to manage and mitigate various health conditions, the medical community often relies on potent pharmaceuticals like steroids, antipsychotics, statins, diuretics ...
‘I feel safe': 2 years in, Inova Pride Clinic exceeds its expectations
NBC Washington· 4 days agoTwo years after opening, Inova Pride Clinic has seen more than 1,100 patients, exceeding...
Lupus Complications Reduced With Common Diabetes Drug
MedPage Today· 6 days agoPeople with systemic lupus erythematosus (SLE) had lower rates of lupus nephritis, chronic kidney disease, and other complications when they were taking metformin, an analysis of medical records ...
Chicago Partners Investment Group LLC Has $45,000 Holdings in Esperion Therapeutics, Inc....
ETF DAILY NEWS· 7 days agoChicago Partners Investment Group LLC cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 48.9% in the 4th quarter, according to its most recent Form 13F filing ...
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Underperform at Bank of America
ETF DAILY NEWS· 5 days agoEsperion Therapeutics (NASDAQ:ESPR – Get Free Report) was downgraded by stock analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research note issued to investors ...
